Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/221671
Title: | Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study |
Author: | Sureda, Anna Garcia Sanz, Ramón Domingo Domènech, Eva Capote, Francisco Javier Gutiérrez García, Antonio Manuel Rodriguez Izquierdo, Antonia Aguiar Bujanda, David Giraldo, Pilar Infante, María Stefania López Jiménez, Javier Martínez, Carmen Sánchez Gonzalez, Blanca Ortiz Romero, Pablo Luís Grande, Marta Baeza Montañez, Lourdes |
Keywords: | Malaltia de Hodgkin Medicaments antineoplàstics Hodgkin's disease Antineoplastic agents |
Issue Date: | 28-Mar-2025 |
Publisher: | MDPI |
Abstract: | Background/Objectives: Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin's lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and CD30-positive cutaneous T-cell lymphoma (CTCL). This study aimed to evaluate the effectiveness and safety of BV retreatment in patients with relapsed/refractory cHL, sALCL, and CD30-positive CTCL. Methods: This multicenter, non-interventional, retrospective medical chart review study analyzed medical records from 43 patients retreated with BV in Spain. Patients were included if they had relapsed or refractory cHL, sALCL, or CD30-positive CTCL and were previously treated with BV. Demographic characteristics, disease stage, response to treatment, survival outcomes, and adverse events were analyzed. Results: The study population included 16 patients with cHL, 13 with sALCL, and 14 with CTCL. The majority were male (58.1%) with a mean age of 46.2 years and baseline ECOG scores of 0-1. Among cHL and sALCL patients, disease stage, according to the Ann Arbor classification, ranged from I to IVB, while in CTCL, EORTC clinical stages ranged from IA to IVB. The overall response rate to BV retreatment was 76.7%, with the highest response observed in sALCL (92.3%). Complete remission was achieved in 60.5% of patients. Median progression-free survival was 25.4 months, and overall survival reached 50 months. Treatment failure occurred in 37.2% of patients. BV was generally well tolerated, with peripheral neuropathy being the most frequently reported adverse event. Conclusions: The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers17071137 |
It is part of: | Cancers, 2025, vol. 17, num. 7 |
URI: | https://hdl.handle.net/2445/221671 |
Related resource: | https://doi.org/10.3390/cancers17071137 |
ISSN: | 2072-6694 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cancers-17-01137-v2.pdf | 1.58 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License